% | $
Quotes you view appear here for quick access.

Amicus Therapeutics, Inc. Message Board

  • vvvvvvrebel89130 vvvvvvrebel89130 Dec 19, 2012 7:52 PM Flag

    fold trading fro .89 minus cash

    $100mm in bank/50mm o/s = $2.00/shr in cash
    $2.89 current price
    $2.00 in cash
    $.89 value of the technology, company assets, paper clips, toilet paper etc

    is what's left worth 89 pennies?

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • With a GSK committment, they would have discontinued partnership if thought otherwise. IMO

      Global Head of GSK Rare Diseases "committed" accrording to PR.

      "Marc Dunoyer, Global Head of GSK Rare Diseases added, "GSK and Amicus are committed to advancing migalastat HCl as a monotherapy in Fabry patients with amenable mutations. While these 6-month data are encouraging, there is additional work to be done. We continue to analyze the 6-month results and look forward to receiving the 12-month results from this study. In addition the results of Study 012, our second Phase 3 Fabry monotherapy study, will add to the totality of our data and give us a more complete picture of the clinical effect of migalastat HCl. This study, an 18-month comparison of migalastat to ERT, with iohexol GFR as the primary endpoint, is fully recruited and due to report in 2014."

6.80-0.33(-4.63%)Jul 28 4:00 PMEDT